<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
Pharmacokinetics and bioavailability of marbofloxacin in lambs following administration of intravenous, intramuscular and subcutaneous

dc.contributor.authorAltan, Feray
dc.contributor.authorCorum, Orhan
dc.contributor.authorCorum, Duygu Durna
dc.contributor.authorAtik, Orkun
dc.contributor.authorUney, Kamil
dc.date.accessioned2026-01-05T22:47:56Z
dc.date.issued2018-02-01
dc.description.abstractAbstract In this study, the pharmacokinetic disposition and bioavailability of marbofloxacin (MB) were determined in lambs after single intravenous (IV), intramuscular (IM), and subcutaneous (SC) administrations at a dose of 3 mg/kg. The plasma concentration of MB was measured using high-performance liquid chromatography-UV, and the pharmacokinetic parameters were analyzed using a non-compartmental analysis. Following IV, IM, and SC administrations, the mean terminal half-life (t1/2ʎz) was 11.48, 12.64, and 24.86 h, respectively, and the mean residence time (MRT) was 7.27, 7.81, and 10.11 h, respectively. The bioavailability (F) was 96.01 and 126.39%, after IM and SC administration, respectively. This study showed that SC administration of MB at a dose of 3 mg/kg exhibited flip-flop pharmacokinetics in lambs. These results suggested that MB could be useful in the treatment of severe systemic infections, such as those with M. haemolytica (MIC = 0.035 μg/mL), in lambs since high AUC0-24/MIC and Cmax/MIC ratios were achieved after IV and IM administration at 3 mg/kg. However, MB administration (3 mg/kg) via the IV, IM, and SC routes might not be effective in the treatment of respiratory infections caused by organisms with MIC90 value in lambs.
dc.description.urihttps://doi.org/10.1016/j.smallrumres.2017.12.004
dc.description.urihttps://dx.doi.org/10.1016/j.smallrumres.2017.12.004
dc.description.urihttps://avesis.deu.edu.tr/publication/details/d6688b1d-5f2f-41b3-8ded-8507a7c6f5c8/oai
dc.description.urihttps://hdl.handle.net/11468/16047
dc.description.urihttps://hdl.handle.net/20.500.12395/36837
dc.identifier.doi10.1016/j.smallrumres.2017.12.004
dc.identifier.endpage10
dc.identifier.issn0921-4488
dc.identifier.openairedoi_dedup___::124ca2e32a6d64f83e3b22e90ba91973
dc.identifier.orcid0000-0002-9017-763x
dc.identifier.orcid0000-0003-3168-2510
dc.identifier.orcid0000-0003-2411-7492
dc.identifier.orcid0000-0002-8674-4873
dc.identifier.scopus2-s2.0-85037992216
dc.identifier.startpage5
dc.identifier.urihttps://hdl.handle.net/20.500.12597/43366
dc.identifier.volume159
dc.identifier.wos000425074600002
dc.language.isoeng
dc.publisherElsevier BV
dc.relation.ispartofSmall Ruminant Research
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectLamb
dc.subjectPharmacokinetics
dc.subjectMarbofloxacin
dc.subjectFluoroquinolones
dc.subject.sdg3. Good health
dc.titlePharmacokinetics and bioavailability of marbofloxacin in lambs following administration of intravenous, intramuscular and subcutaneous
dc.typeArticle
dspace.entity.typePublication
local.import.sourceOpenAire
local.indexed.atWOS
local.indexed.atScopus

Files

Collections